Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies

Mazdak M Bradberry^{1

2}, Natalie Gukasyan^{3

4}, Charles L Raison⁵

Affiliations

¹ Department of Neuroscience, University of Wisconsin School of Medicine and Public Health, Madison.
² Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison.
³ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.
⁴ Center for Psychedelic and Consciousness Research, Johns Hopkins Bayview Medical Center, Baltimore, Maryland.
⁵ School of Human Ecology, University of Wisconsin-Madison, Madison.

Mazdak M Bradberry et al. JAMA Psychiatry. 2022.

. 2022 Jun 1;79(6):525-527.

doi: 10.1001/jamapsychiatry.2022.0665.

Mazdak M Bradberry^{1

2}, Natalie Gukasyan^{3

4}, Charles L Raison⁵

¹ Department of Neuroscience, University of Wisconsin School of Medicine and Public Health, Madison.
² Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison.
³ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.
⁴ Center for Psychedelic and Consciousness Research, Johns Hopkins Bayview Medical Center, Baltimore, Maryland.
⁵ School of Human Ecology, University of Wisconsin-Madison, Madison.

No abstract available

References

1. Bender D, Hellerstein DJ. Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology. Published online January 13, 2022. doi:10.1007/s00213-021-06049-6 - DOI - PubMed
1. Jerome L, Feduccia AA, Wang JB, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology. 2020;237(8):2485–2497. doi:10.1007/s00213-020-05548-2 - DOI - PMC - PubMed
1. Cohen S, Ditman Keith. Prolonged Adverse Reactions to Lysergic Acid Diethylamide. Arch Gen Psychiatry. 1963;8(5):475. doi:10.1001/archpsyc.1963.01720110051006 - DOI - PubMed
1. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620. doi:10.1177/0269881108093587 - DOI - PMC - PubMed
1. Strassman RJ. Adverse reactions to psychedelic drugs. The Journal of Nervous and Mental Disease. 1984;172(10):577–595. doi:10.1097/00005053-198410000-00001 - DOI - PubMed